MedtronicNYSE: MDT

The new Smart MDI system will be the first to provide real-time, personalized information on when and how much to dose, even for missed or incorrect mealtime doses. Medtronic plc, a leader in healthcare technology, announced that the U.S. Food and Drug Administration (FDA) has approved its InPen™ app, which includes missed meal dose detection. This approval paves the way for the launch of the Smart MDI system alongside the Simplera™ continuous glucose monitor (CGM).

Medtronic plc announced its Q2 earnings today, showing revenues of $8.4 billion, which is a 5% increase compared to last year, and an adjusted EPS of $1.26, along with a dividend yield of 3.2%. Although the company has experienced steady revenue growth and introduced new products, its share price has not changed much due to variable net income and limited innovation. CEO Geoff Martha pointed out the company's strong performance in areas like diabetes and hypertension but did not give specific long-term growth predictions, leaving market feelings somewhat neutral.

U.S. stocks showed mixed results as trading came to a close, with the Nasdaq Composite rising by about 1% on Tuesday.

Medtronic plc (NYSE:MDT) will hold its Q2 2025 Earnings Conference Call on November 19, 2024, at 8:00 AM ET. Key company participants include CEO Geoff Martha and several executive vice presidents overseeing different divisions. Ryan Weispfenning, the Vice President of Investor Relations, will lead the call and welcomes everyone to the Fiscal '25 Second Quarter Video Earnings Webcast.

Medtronic plc has shared its financial results for the second quarter of fiscal year 2025, which ended on October 25, 2024. The company reported a revenue of $8.4 billion, showing a 5.3% increase overall and a 5.0% rise on an organic basis. Additionally, Medtronic has raised its guidance for organic revenue growth and earnings per share for the fiscal year.

On the most recent trading day, Medtronic (MDT) closed at $87.53, which is an increase of 1.78% compared to its last closing price.

A surgeon from Beverly Hills is taking legal action against Medtronic, alleging that they have infringed on her patent for a hernia repair mesh product. This lawsuit is part of a growing number of patent disputes involving Medtronic.

On the most recent trading day, Medtronic (MDT) closed at $87.72, which is a decrease of 0.45% compared to its last closing price.

Similar to other companies, the current geopolitical situation might have limited Medtronic's profits in the second quarter.